Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Michigan Prior Auth Policy …
    Ask Trek AI about this page
    Currentblue cross blue shield - michiganPolicy N/A

    Acitretin and selected specialty drug prior authorization and step therapy criteria

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Outlines prior authorization and step therapy requirements, coverage durations (commonly 1 year), prerequisite Part D drug and documentation expectations for acitretin and multiple specialty/Part D products for Medicare Plus Blue Group PDP/PPO plans.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin and selected specialty drug prior authorization and step therapy criteria
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionSubmit prior authorization requests with required documentation of diagnosis and prerequisite therapy trials (where specified) to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20+Docs in extract
    Requires PA/STPA/ST required
    1 YEARTypical duration
    >=12

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age example

    Coverage Criteria and Product Summaries

    Initial Authorization Criteria (product summaries)

    Covered when product-specific PA criteria are met; coverage duration generally 1 year unless otherwise stated.

    Acitretin: prior authorization required; coverage duration 1 year; criteria does not require a prerequisite Part D drug.

    chunk 2

    Adbry (Adbry): prior authorization required; indication: atopic dermatitis for patients at least 12 years of age with moderate to severe disease; requires trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil; cannot be used in combination with another biologic/targeted DMARD for the same condition; reauthorization requires documentation of positive clinical response; dosing limits apply for patients <100 kg after 16 weeks; criteria requires use of a prerequisite Part D drug.

    chunk 5

    Alpha-1-proteinase inhibitors: Prolastin‑C (alpha‑1‑proteinase inhibitor): prior authorization required for necrotizing panniculitis or alpha‑1 antitrypsin deficiency with symptomatic emphysema; patient must be ≥18 years; documentation of congenital AAT deficiency consistent with phenotypes PIZZ, PIZ (null), or PI (null,null) is required; FEV1 less than 80% predicted is specified as required medical information; criteria does not require a prerequisite Part D drug.FEV1 < 80% predicted

    chunk 19

    Prolastin-c (Alpha-1-proteinase inhibitor) Initial Criteria

    Prolastin-c coverage requires ALL of the following:

    Prolastin-c coverage criteria: 1) Diagnosis of necrotizing panniculitis or documented alpha‑1 antitrypsin deficiency with symptomatic emphysema; 2) FEV1 less than 80% predicted; 3) Documentation of congenital AAT deficiency consistent with phenotypes PIZZ, PIZ (null), or PI (null, null); 4) Patient age 18 years or older.

    chunk 19

    Alunbrig Initial Criteria

    Alunbrig coverage requires:

    Alunbrig coverage criteria: Coverage for treatment of ALK‑positive metastatic non‑small cell lung cancer as described in product entry; prior therapy with crizotinib is required (prerequisite Part D drug).

    chunk 21

    Arcalyst Initial Criteria

    Arcalyst coverage for recurrent pericarditis requires:

    Arcalyst coverage criteria: Trial of a nonsteroidal anti‑inflammatory drug in combination with colchicine is required prior to Arcalyst coverage.

    chunk 22

    Auvelity Initial Criteria

    Auvelity coverage for major depressive disorder requires:

    Auvelity coverage criteria: Prior use of another generic formulary antidepressant is required (prerequisite Part D drug).

    chunk 29

    Balversa Initial Criteria

    Balversa coverage requires:

    Balversa coverage criteria: Treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations and documentation of trial of at least one prior systemic therapy.

    chunk 35

    Banzel Initial Criteria

    Banzel coverage requires:

    Banzel coverage criteria: Coverage requires documented trial of divalproex (or equivalent) prior to approval (prerequisite Part D drug).

    chunk 36

    Initial coverage criteria by product (partial list)

    Coverage for the listed products is subject to PA and, where specified, requires evidence of prior therapy or combination use as noted below.

    Banzel (rufinamide): Coverage requires trial of divalproex or other specified prerequisite Part D drug.

    chunk 36

    Benlysta (belimumab): Covered for medically accepted indications with prior authorization; coverage duration 1 year.

    chunk 38

    Besremi: Coverage for polycythemia vera per product entry; prerequisite Part D drug trial required.

    chunk 40

    Bosulif: Coverage for accelerated/blast phase Ph+ CML requires trial of prior therapy (prerequisite Part D drug required).

    Indication-specific Coverage Criteria

    Cabometyx coverage conditions: Coverage duration one year; for first‑line advanced renal cell carcinoma, combination use with nivolumab is required; for hepatocellular carcinoma a prior trial of sorafenib is required; for locally advanced or metastatic differentiated thyroid cancer that is radioactive iodine‑refractory or ineligible, a trial of VEGFR‑targeted therapy is required; criteria requires use of a prerequisite Part D drug.

    chunk 55

    Glatopa (Glatiramer Acetate)

    Glatiramer acetate (Glatopa)

    Glatopa coverage: Coverage for all medically‑accepted indications; prior authorization required; coverage duration 1 year; prerequisite Part D drug not required.

    chunk 74

    Copiktra

    Copiktra (duvelisib)

    Copiktra coverage: Coverage for relapsed or refractory CLL requires at least two prior therapies; prior authorization required; prerequisite Part D drug required.

    chunk 76

    Cosentyx (secukinumab) — indication-specific criteria

    Cosentyx (secukinumab)

    Psoriatic Arthritis: Diagnosis of active psoriatic arthritis required; prior authorization; coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    chunk 79

    Plaque Psoriasis: Diagnosis of moderate to severe chronic plaque psoriasis required for coverage.

    chunk 79

    Ankylosing Spondylitis: Diagnosis of ankylosing spondylitis and trial of one NSAID prior to biologic required.

    chunk 79

    Non-radiographic axSpA: Diagnosis with objective signs of inflammation and trial of one NSAID required prior to biologic.

    chunk 79

    Cotellic

    Cotellic (cobimetinib)

    Melanoma coverage: Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K mutation; vemurafenib referenced as prerequisite therapy; criteria indicates no prerequisite Part D drug required.

    chunk 83

    Cresemba and Cystaran

    Cresemba (isavuconazole) and Cystaran (cysteamine)

    General coverage: Coverage for all medically‑accepted indications; prior authorization required; coverage duration 1 year; prerequisite Part D drug not required.

    chunks 86,88

    Dalfampridine

    Dalfampridine

    Dalfampridine coverage: Coverage for treatment of multiple sclerosis requires documentation of a baseline Timed 25‑Foot Walk (T25FW) test prior to initiation; excluded if the patient is wheelchair‑bound or becomes wheelchair‑bound; prior authorization required; criteria does not require a prerequisite Part D drug.

    chunk 90

    Dalfampridine — Baseline functional test requirement

    Dalfampridine (Dalfampridine ER): covered when ALL of the following are met

    Dalfampridine MS coverage criteria: Patient is being treated for multiple sclerosis AND documentation of a baseline Timed 25‑Foot Walk (T25FW) test prior to initiation.

    chunk 90

    Diacomit — Trial and combination requirement

    Diacomit: covered when ALL of the following are met

    Diacomit coverage criteria: Documented trial of two generic anticonvulsants AND combination use with clobazam as required.

    chunk 96

    Dihydroergotamine — Triptan trial requirement

    Dihydroergotamine nasal spray: covered when ALL of the following are met

    Dihydroergotamine coverage criteria: Documented trial of two triptans on the formulary, including one oral triptan and one non‑oral triptan.

    chunk 98

    Drizalma — Coverage duration

    Drizalma Sprinkle: coverage details provided

    Drizalma coverage: Prior authorization required; coverage duration 1 year.

    chunk 101

    Dupixent — Indication- and trial-based coverage

    Dupixent: covered when indication-specific criteria are met

    Dupixent general criteria: Diagnosis for the specific FDA‑approved or medically‑accepted indication AND age/weight requirements per indication AND required prior therapy/trial(s) specific to each indication (as listed) AND reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for the same condition.

    chunks 105-107

    Ebglyss (selected detailed criteria)

    Ebglyss (acitretin section entry) coverage details

    Ebglyss main criteria: Patient must weigh at least 40 kg and be at least 12 years of age; cannot be used in combination with another biologic/targeted DMARD for the same condition; coverage duration 1 year; for atopic dermatitis (≥12 years) requires diagnosis of moderate to severe AD and trial and failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil; criteria requires use of a prerequisite Part D drug.

    chunk 110

    Enbrel

    Enbrel coverage details

    Enbrel RA criteria: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); for ankylosing spondylitis requires trial of an NSAID; for polyarticular JIA requires trial of methotrexate or leflunomide; reauthorization requires documentation of positive clinical response; criteria requires use of a prerequisite Part D drug.

    chunks 116-117

    Epidiolex

    Epidiolex coverage details

    Epidiolex seizure disorders: Coverage for Lennox‑Gastaut syndrome requires trial of two generic alternatives; for Dravet syndrome requires trial of two of: valproic acid, clobazam, or topiramate; for seizures associated with tuberous sclerosis complex requires trial of two generic alternatives; prerequisite Part D drug required.

    chunk 123

    Miscellaneous products

    Other product criteria highlights

    Emsam: Coverage requires trial with two of the specified agents per product entry (prerequisite Part D drug required).

    chunk 114

    Ensacove: Standard prior authorization with 1 year coverage duration; prerequisite Part D drug not required per entry.

    chunk 121

    Erivedge: Prescribing physician must be an oncologist or dermatologist; coverage duration 1 year; prerequisite Part D drug not required.

    chunk 127

    Fasenra coverage criteria

    Covered when ALL of the following indication-specific requirements are met:

    Fasenra overall

    • Eosinophilic Asthma (EA): Diagnosis of EA and eosinophil count ≥150 cells/µL at initiation AND failure to maintain adequate control after trial of systemic corticosteroids or high‑dose inhaled corticosteroids in combination with trial of one additional asthma controller (leukotriene modifier OR LABA OR LAMA) in adults and children ≥12 years.>=150 cells/µL

      chunk 142

    • EGPA: Diagnosis of eosinophilic granulomatosis with polyangiitis with history or presence of asthma and documentation of typical EGPA features (e.g., histopathology, organ manifestations).

      chunk 142

    • HES: Diagnosis of hypereosinophilic syndrome with eosinophil count ≥1000 cells/µL at initiation.

    Fetzima — Initial Authorization

    Covered when ALL of the following are met

    Fetzima (Initial): Coverage for treatment of major depressive disorder requires documented trials of desvenlafaxine and duloxetine (prerequisite Part D drugs).

    chunk 145

    Gilotrif — Covered indication

    Covered when ALL of the following are met

    Gilotrif coverage: Coverage provided as first‑line treatment for patients with metastatic NSCLC whose tumors have non‑resistant EGFR mutations as detected by an FDA‑approved test.

    chunk 164

    GLP-1 agonists — Covered indications and exclusions

    Covered when ALL of the following are met

    GLP-1 agonists coverage: Indication is a medically‑accepted use for type 2 diabetes mellitus; submit medical records confirming T2DM diagnosis or lab evidence (A1c ≥6.5%, fasting plasma glucose ≥126 mg/dL, or 2‑hour plasma glucose ≥200 mg/dL); excluded if used for weight‑loss‑only; coverage duration 1 year.

    chunk 165

    Humira — Condition-specific coverage requirements

    Covered when ALL of the following are met

    Humira coverage for RA: Diagnosis of moderately to severely active rheumatoid arthritis and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) required; cannot be used in combination with another biologic/targeted DMARD for the same condition; coverage duration typically 1 year.

    chunk 181

    Humira coverage for polyarticular JIA: Diagnosis of active polyarticular juvenile idiopathic arthritis and trial of methotrexate or leflunomide required; coverage duration 1 year.

    chunk 181

    Humira coverage for AS: Diagnosis of active ankylosing spondylitis and trial of one NSAID required prior to biologic therapy; coverage duration 1 year.

    chunk 181

    Other specialty products — general coverage notes

    Covered when ALL of the following are met

    Other listed products: Indications are medically‑accepted for each product; typical coverage duration is 1 year (pediatric Genotropin = 1 year; adult growth hormone = lifetime where noted); prerequisite therapy not required for many products unless specified in the product entry.

    chunks 167-178

    Product-specific coverage criteria

    Coverage is provided for listed products when specific indication and prerequisite therapy requirements described for each product are met. Reauthorization generally requires evidence of positive clinical response.

    General PA and coverage duration: Prior authorization required; coverage duration commonly 1 year for listed products.

    chunks 181-198

    Combination Exclusion: Product cannot be used in combination with another biologic or targeted DMARD indicated for the same condition where stated.

    chunk 181

    Reauthorization requires documentation of positive clinical response to therapy where specified.

    chunk 182

    RA prerequisite therapy: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine).

    Imkeldi — Coverage with criteria

    Coverage statements and prerequisites for specific products (partial):

    Imkeldi coverage: Coverage for all indications requires that the patient is unable to swallow tablet formulation OR is unable to achieve the prescribed dose with tablet formulation; some indications note prerequisite therapy requirements.

    chunk 198

    Inlyta — Combination therapy requirement

    Inlyta first-line RCC: Coverage for first‑line treatment of advanced renal cell carcinoma requires combination use with avelumab or pembrolizumab; prior authorization required and prerequisite Part D drug required for some indications.

    chunk 206

    Isotretinoin — Prerequisite therapy

    Isotretinoin prerequisites: Coverage requires trial of either an oral antibiotic OR a benzoyl peroxide topical prior to initiation.

    chunk 214

    Itovebi — Coverage note (incomplete)

    Itovebi coverage note: Coverage for endocrine‑resistant, PIK3CA‑mutated HR‑positive, HER2‑negative disease references fulvestrant as part of prerequisite therapy; source text truncated in extract.

    chunk 216

    Product-level coverage summaries

    Coverage is generally provided for medically-accepted or FDA-approved indications with specific prerequisite therapy or prior-treatment requirements for certain drugs/indications.

    General: Provide prior authorization and documentation that the indication is medically‑accepted or FDA‑approved as listed for each product.

    chunks 216-234

    Polycythemia vera (Jakafi): Coverage requires inadequate response or intolerance to hydroxyurea for polycythemia vera.

    chunk 225

    Mantle cell lymphoma (Jaypirca): Coverage requires trial of two lines of systemic therapy including a BTK inhibitor.

    chunk 227

    Jylamvo indications: Coverage requires a trial of methotrexate tablet prior to approval.

    Kerendia — Covered when ALL of the following are met

    Kerendia: Coverage conditions

    Kerendia coverage: Coverage provided for chronic kidney disease associated with type 2 diabetes; for treatment of heart failure with LVEF ≥40% requires trial of an SGLT2 inhibitor unless contraindicated or intolerant; coverage duration 1 year.

    chunk 236

    Kevzara — Indication-specific criteria

    Kevzara: Indication-specific prerequisites and reauthorization

    Kevzara RA: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of two of the following: Enbrel, adalimumab formulations, Rinvoq, Xeljanz/XR, Orencia; cannot be used in combination with another biologic/targeted DMARD for the same condition; reauthorization requires documentation of positive clinical response; prerequisite Part D drug required.

    chunks 241-242

    Kevzara PMR: Coverage for polymyalgia rheumatica requires history of corticosteroid treatment >10 mg/day prednisone equivalent for ≥8 weeks AND inadequate response or intolerance as demonstrated by disease flare during corticosteroid taper at >7.5 mg/day prednisone equivalent.

    chunk 241

    Kevzara polyarticular JIA: Coverage for polyarticular juvenile idiopathic arthritis requires diagnosis of active polyarticular JIA and trial of two of: Enbrel, adalimumab formulations, Xeljanz/XR, Orencia; reauthorization requires documentation of positive clinical response.

    chunk 241

    Kineret — RA coverage criteria

    Kineret: Rheumatoid arthritis coverage

    Kineret RA: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of two of: Enbrel, adalimumab formulations, Rinvoq, Xeljanz/XR, Orencia; prerequisite Part D drug required; coverage duration 1 year.

    chunk 245

    Kisqali — Covered when specific combination endocrine therapy conditions met

    Kisqali: Breast cancer coverage conditions

    Kisqali advanced/metastatic HR+/HER2-: Coverage for HR‑positive, HER2‑negative advanced or metastatic breast cancer requires combination with an aromatase inhibitor as initial endocrine‑based therapy OR fulvestrant as initial endocrine‑based therapy OR following progression on endocrine therapy; coverage duration 1 year; prerequisite Part D drug required.

    chunks 246-247

    Kisqali early-stage high risk: Coverage for stage II/III early breast cancer at high risk of recurrence requires combination use with an aromatase inhibitor; coverage duration 1 year.

    chunk 247

    Product-level coverage criteria (summaries)

    Product-specific PA summaries with stated indications, prerequisites, and durations

    Koselugo: Coverage for medically‑accepted indications; duration 1 year; no prerequisite Part D drug required.

    chunk 254

    Krazati: Coverage for KRAS G12C‑mutated locally advanced or metastatic NSCLC requires prior systemic therapy; prerequisite Part D drug required.

    chunk 256

    Lazcluze: Coverage for specified locally advanced disease requires combination use with amivantamab; criteria indicates no prerequisite Part D drug required.

    chunk 258

    Lenvima: Coverage for specified RCC and endometrial carcinoma indications requires combination with pembrolizumab or everolimus and may require prior anti‑angiogenic therapy; prerequisite Part D drug required; coverage duration 1 year.

    The source extract indicates that for many products in this segment Off‑label uses are listed as N/A, i.e., no off‑label use criteria are provided in the excerpt. Where an off‑label field is shown as N/A in the document, there are no specific off‑label authorization rules in this partial extract to support coverage decisions beyond the listed medically‑accepted indications.

    The document explicitly states that coverage will not be provided for maintenance of remission in ulcerative colitis with budesonide ER. This is an explicit exclusion in the budesonide ER product entry and should be applied when evaluating requests for maintenance‑of‑remission use.

    No additional miscellaneous coverage notes are present in this excerpt for the referenced product beyond the itemized indication‑specific combination and prerequisite therapy statements already captured in the product entry.

    Dalfampridine is excluded for use if the patient is wheelchair bound or becomes wheelchair bound. This explicit exclusion appears in the dalfampridine product entry and should be enforced when evaluating eligibility.

    Multiple biologic product entries (for example Cosentyx, Ebglyss, Fasenra, Humira, Kevzara) state that the agent cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. Apply this concurrent‑biologic exclusion when a request documents planned combination use with another biologic/targeted DMARD for the same diagnosis.

    This entry duplicates the dalfampridine exclusion: the product is not covered if the patient is wheelchair bound or becomes wheelchair bound, per the dalfampridine PA notes.

    Several product summaries include a common restriction: use in combination with another biologic or targeted DMARD indicated for the same condition is not allowed. Where the product entry contains that statement, concurrent biologic/targeted DMARD combinations should be considered non‑covered.

    The Fasenra product entry specifically notes that it cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. Enforce this exclusion when assessing Fasenra requests that propose concurrent use with another biologic/targeted DMARD.

    In the excerpt provided there is no explicit exclusion statement for Fetzima; the Fetzima entry documents prerequisite Part D drugs (desvenlafaxine and duloxetine) but does not list a combination‑therapy exclusion in this partial extract.

    The GLP‑1 agonist group entry states an explicit exclusion: these agents are excluded if used for the treatment of weight loss only. For requests that indicate weight‑loss‑only use, coverage should be denied per the excerpted policy language.

    The Humira entry contains a combination‑therapy exclusion: Humira cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. Apply this restriction when requests propose concurrent biologic/targeted DMARD therapy for the same diagnosis.

    Many biologic product entries repeat the combination‑use exclusion language (e.g., Cosentyx, Ebglyss, Enbrel, Humira): where present the policy states the agent cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. This is a common, product‑level exclusion in the provided extract.

    Across multiple product summaries in this extract the Off‑Label Uses field is shown as N/A, indicating that for those entries there are no off‑label use criteria listed in the partial excerpt. Where Off‑Label Uses = N/A, no separate off‑label authorization rules are available in the provided text.

    Many product summaries in this portion of the document either list 'N/A' for Off‑Label Uses and Exclusion Criteria or contain no explicit exclusion language. Where an entry shows 'N/A' or the exclusion field is blank in the excerpt, there is no excerpted basis to apply an exclusion beyond those explicitly stated.

    The Kevzara entry explicitly states that it cannot be used in combination with another biologic or targeted DMARD indicated for the same condition. Enforce this exclusion when evaluating Kevzara requests that propose concurrent biologic/targeted DMARD therapy for the same diagnosis.

    The extract repeats entries where Off‑label uses are listed as N/A for multiple products; these repeats indicate that no off‑label criteria are provided in the partial text for those items.

    In the Ebglyss (acitretin) section of the extract there is no explicit 'not medically necessary' statement included; the product entry shows Off‑Label Uses and Exclusion Criteria as N/A but does not present a discrete NMN clause in the provided chunks.

    For Diacomit the excerpt documents required prior trials and combination use (trial of two generic anticonvulsants and combination with clobazam) but there is no separate 'not medically necessary' statement in the provided text beyond those prerequisite requirements.

    Prior Authorization, Documentation, and Denial Risks — What Providers Must Do

    Prior Authorization

    Acitretin — Prior authorization required

    Acitretin requires prior authorization; coverage duration is 1 year and no prerequisite Part D drug is required.

    Prior Authorization

    Adbry — PA with age and trial requirements

    Adbry requires prior authorization for atopic dermatitis in patients at least 12 years of age and cannot be used in combination with another biologic or targeted DMARD for the same condition; approval requires trial and treatment failure of one listed topical or systemic therapy.

    • Age restriction: at least 12 years
    • Trial and treatment failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil
    • Cannot be used in combination with another biologic/targeted DMARD

    Initial Therapy / First Authorization Requirements

    Reauthorization and Continuation Requirements

    Step Therapy / Prerequisite Drug Requirements

    Coverage labelExplanation
    ST flag on formularyDrugs identified with (ST) on the formulary require prior treatment with one or more specified formulary drugs before coverage is provided. See individual product entries for the specific prerequisite agents and trial requirements.
    How ST interacts with PASome products are subject to both prior authorization (PA) and step therapy (ST); meeting clinical PA criteria plus documentation of required prior/formulary therapy (per ST) is required for approval.
    Provider actionPhysicians should consult the formulary to confirm ST/PA status and contact the pharmacy help desk to request prior authorization or document required prior therapy trials as part of the PA submission.
    Coverage labelStep therapy requirement
    Adbry for atopic dermatitisRequires prior authorization. For atopic dermatitis in patients ≥12 years, coverage requires diagnosis of moderate to severe AD and a trial and treatment failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil. Criteria requires use of a prerequisite Part D drug.
    Eucrisa (related topical alternative)Eucrisa requires a trial of one generic topical steroid prior to coverage for atopic dermatitis, as an example of the required formulary alternative prior to biologic or second-line agents.
    Coverage labelRequired prior therapy
    Auvelity for major depressive disorderCoverage requires prior use of another generic formulary antidepressant (prerequisite Part D drug) before Auvelity will be approved.
    Product (example)Trial / combination requirement
    Banzel (rufinamide)Coverage requires trial of divalproex (or equivalent) prior to approval (prerequisite Part D drug).
    Braftovi (encorafenib)Certain melanoma and other indications require combination use (e.g., with binimetinib) and prior vemurafenib + cobimetinib in some settings; prerequisite Part D drug required.
    Briviact (brivaracetam)Coverage requires trial of levetiracetam and one other specified agent prior to approval (prerequisite Part D drug).
    Cabometyx (cabozantinib)First-line advanced RCC requires combination use with nivolumab; HCC requires prior trial of sorafenib; radioactive iodine–refractory DTC requires trial of VEGFR-targeted therapy. Prerequisite Part D drug required where noted.
    Coverage labelPrior trial required (indication examples)
    First-line advanced RCC (Cabometyx)Requires combination use with nivolumab for first-line advanced renal cell carcinoma.
    Hepatocellular carcinoma (Cabometyx)Requires prior trial of sorafenib before coverage is provided.
    Differentiated thyroid cancer (Cabometyx)Locally advanced or metastatic radioiodine-refractory or ineligible DTC requires a trial of VEGFR-targeted therapy prior to coverage.
    Coverage labelPrior trial required
    Arcalyst for recurrent pericarditisCoverage requires trial of a nonsteroidal anti-inflammatory drug in combination with colchicine prior to Arcalyst approval.
    Coverage labelPrior therapy history required
    Copiktra (duvelisib)Coverage for relapsed or refractory CLL requires history of at least two prior therapies before Copiktra will be approved.
    Coverage labelStep therapy requirement
    Dihydroergotamine nasal sprayCoverage requires documented trial of two triptans on the formulary: one oral triptan and one non-oral triptan prior to approval.
    Product groupCommon prerequisite requirement
    Antiepileptics (examples)Several anticonvulsant or antiepileptic agents require documented trials of specified generic alternatives (e.g., Briviact requires levetiracetam trial).
    Oncology targeted agents (examples)Many oncology agents require prior systemic therapy or combination use depending on indication (e.g., Braftovi, Cabometyx, Lenvima); prerequisite Part D drugs or combination partners are often required.
    Psychotropic agents (examples)Antipsychotic products (e.g., Bysanti, Fanapt) require trials of specified generic atypical antipsychotics prior to coverage.
    Coverage labelPrerequisite example
    Drizalma SprinklePrior authorization applied; coverage duration listed as 1 year (example of common coverage duration for many products).
    Cabometyx indicationsExample reminder that specific indications may require prior trials or combination therapy per product entry (see Cabometyx: nivolumab combination, sorafenib trial, VEGFR-targeted therapy trial).
    Coverage labelRequired prior therapy
    Eucrisa for atopic dermatitisCoverage requires a trial of one topical steroid (generic) prior to approval; coverage duration 1 year.
    Coverage labelStep therapy requirement
    Fanapt for schizophreniaCoverage requires documented trials of two generic formulary atypical antipsychotics (examples listed include quetiapine, risperidone, ziprasidone) prior to approval.
    Coverage labelRequired prior therapy / controller
    Fasenra for eosinophilic asthmaCoverage requires diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation and failure to maintain control after trial of systemic corticosteroids or high-dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier OR LABA OR LAMA).
    Fasenra other indications (EGPA/HES)Indication-specific diagnostic criteria apply (EGPA: typical features; HES: eosinophil count ≥1000 cells/µL). Reauthorization requires documented positive clinical response.
    Coverage labelPrerequisite Part D drugs
    Fetzima (major depressive disorder)Coverage requires prior documented trials of desvenlafaxine and duloxetine (prerequisite Part D drugs) before Fetzima will be approved.
    Coverage labelNote (duplicate)
    Fetzima prerequisite drugs (duplicate)As noted in the Fetzima entry, prerequisite trials of desvenlafaxine and duloxetine are required prior to coverage; documentation of these trials should be included in the PA request.
    Coverage labelDMARD / NSAID trial requirement
    Humira for rheumatoid arthritisCoverage for RA requires trial of at least one disease-modifying antirheumatic drug (DMARD) such as methotrexate, leflunomide, or sulfasalazine prior to Humira approval.
    Humira for ankylosing spondylitisCoverage for AS requires trial of one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen) prior to biologic therapy.
    Coverage labelGeneral prior trials required
    PA with prerequisite therapy (general)Many products require prior trials of specified agents or Part D drugs and documentation of those trials as part of the PA request; coverage durations are commonly 1 year.
    Coverage labelRequired prior therapy
    Isotretinoin (Accutane and brands)Coverage requires trial of either an oral antibiotic OR a benzoyl peroxide–containing topical prior to isotretinoin approval.
    Coverage labelMCL step therapy
    Jaypirca for mantle cell lymphoma (MCL)Coverage requires documented trial of two lines of systemic therapy, including a BTK inhibitor, prior to approval.
    Coverage labelPrerequisite
    JylamvoCoverage requires a trial of methotrexate tablets prior to approval; document trial in the PA request.
    Group exampleGrouped prerequisite therapies
    KevzaraIndication-specific prerequisites: RA and other indications require trials of specified biologics/DMARDs (e.g., Enbrel, adalimumab products, Rinvoq, Xeljanz/XR, Orencia); reauthorization requires positive clinical response.
    KineretRA coverage requires trial of two of listed biologics/DMARDs prior to approval; prerequisite Part D drug required.
    Kerendia (group example)For HFpEF (LVEF ≥40%) indication, requires trial of an SGLT2 inhibitor unless contraindicated; other CKD/T2DM criteria apply per product entry.

    Clinical Thresholds and Coding-Adjacent Key Values

    inv-65: FEV1 threshold for Prolastin-c
    ThresholdFEV1 < 80% predicted
    Required diagnosisNecrotizing panniculitis or alpha-1 antitrypsin deficiency
    DocumentationCongenital AAT deficiency phenotype consistent with PIZZ, PIZ (null), or PI (null, null)
    Age requirementPatients 18 years of age or older
    inv-66: Eosinophil count thresholds (Fasenra/HES)
    Eosinophilic asthma (initiation)>=150 cells/µL at initiation
    Hypereosinophilic syndrome (HES)

    Definitions, Background, and Scope

    This document lists drugs subject to prior authorization and/or step therapy in the Medicare Plus Blue Group PDP/PPO formularies to ensure appropriate and cost‑effective therapy. Clinical and administrative criteria (e.g., prerequisite Part D drug trials, baseline diagnostic tests, combination‑therapy requirements, and explicit exclusions) are used to determine coverage. For many products the typical coverage duration is 1 year and PA or ST is required prior to approval.

    inv-176: Prior Authorization (PA) definition
    DefinitionA requirement that clinical and/or administrative criteria must be met before coverage is provided for certain drugs.
    PurposeEnsures appropriate and cost-effective drug therapy by verifying clinical eligibility prior to coverage.
    How to requestPhysician must contact the pharmacy help desk to request prior authorization; refer to the formulary to verify coverage.
    inv-177: Step Therapy (ST) definition
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin and selected specialty drug prior authorization and step therapy criteria
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionSubmit prior authorization requests with required documentation of diagnosis and prerequisite therapy trials (where specified) to avoid denial.
    SourceLink
    On This Page
    Coverage Criteria and Product SummariesPrior Authorization, Documentation, and Denial Risks — What Providers Must DoInitial Therapy / First Authorization RequirementsReauthorization and Continuation RequirementsStep Therapy / Prerequisite Drug RequirementsClinical Thresholds and Coding-Adjacent Key ValuesDefinitions, Background, and Scope

    chunk 44

    Braftovi (encorafenib): Coverage for BRAF V600E/K mutant indications requires combination use (e.g., with binimetinib) and may require prior vemurafenib/cobimetinib in some melanoma settings; prerequisite Part D drug required.

    chunk 46

    Briviact (brivaracetam): Coverage requires trial of levetiracetam and one other specified agent prior to approval (prerequisite Part D drug required).

    chunk 47

    Brukinsa (zanubrutinib): Coverage for mantle cell lymphoma requires trial of Calquence; other lymphoma indications require specified prior therapies; prerequisite Part D drug required.

    chunk 49

    Budesonide ER: Covered for medically accepted indications; explicit exclusion — no coverage for maintenance of remission in ulcerative colitis.

    chunk 51

    Bysanti: Coverage for schizophrenia in adults requires trials of lurasidone and paliperidone; for other indications requires trial of at least two listed generic antipsychotics; prerequisite Part D drug required.

    chunk 53

    Cabometyx (cabozantinib): Coverage: one year duration; first‑line advanced RCC requires combination with nivolumab; HCC requires prior sorafenib; radioiodine‑refractory DTC requires trial of VEGFR‑targeted therapy; prerequisite Part D drug required.

    chunk 55

    Enthesitis-Related Arthritis: Diagnosis of active ERA and trial of one NSAID required.

    chunk 79

    Hidradenitis Suppurativa: Diagnosis of moderate to severe HS required for coverage.

    chunk 80

    >=1000 cells/µL

    chunk 143

    chunk 181

    Iclusig specific rules: Coverage for newly diagnosed Ph+ ALL requires combination with chemotherapy; other chronic phase CML indications require trial of at least two prior kinase inhibitors.

    chunk 192

    Imkeldi oral intolerance: Coverage requires that the patient is unable to swallow tablet formulation or unable to achieve prescribed dose with tablet formulation.

    chunk 198

    chunk 229

    chunk 261

    Leuprolide products: Coverage for medically‑accepted indications; coverage duration 1 year; no prerequisite Part D drug required.

    chunk 263

    Levetiracetam oral suspension: Coverage for patients unable to swallow tablets/capsules as specified; criteria references prerequisite therapy/conditions.

    chunk 266

    Libervant: Coverage for medically‑accepted indications; coverage duration 1 year; no prerequisite Part D drug required.

    chunk 268

    Libtayo: Coverage for basal cell carcinoma requires prior treatment with a hedgehog pathway inhibitor; prerequisite therapy required.

    chunk 270

    Prior Authorization

    Prolastin‑C — PA and diagnostic/FEV1 requirements

    Prolastin‑C (alpha‑1‑proteinase inhibitor) requires prior authorization with documented diagnosis of necrotizing panniculitis or alpha‑1 antitrypsin deficiency, documentation of congenital AAT deficiency phenotype, and FEV1 less than 80% predicted; patient must be 18 years or older and have symptomatic emphysema.

    • Diagnosis: necrotizing panniculitis or AAT deficiency
    • Documentation of congenital AAT phenotype (PIZZ, PIZ null, or PI null/null)
    • FEV1 < 80% predicted
    • Patient age ≥ 18 years
    • Indication: symptomatic emphysema
    Prior Authorization

    Alunbrig — Prerequisite crizotinib trial

    Alunbrig coverage requires prior authorization and a prerequisite trial of crizotinib as the specified Part D therapy before approval.

    • Prerequisite therapy: crizotinib
    Prior Authorization

    Arcalyst — NSAID + colchicine trial required

    Arcalyst for recurrent pericarditis requires prior authorization and documentation of a trial of a nonsteroidal anti‑inflammatory drug used in combination with colchicine prior to coverage.

    • Prerequisite therapy: trial of NSAID in combination with colchicine
    Step Therapy

    Auvelity — Step therapy (prior antidepressant) required

    Auvelity requires prior authorization for major depressive disorder and coverage requires prior use of another generic formulary antidepressant.

    • Prerequisite therapy: another generic formulary antidepressant
    Prior Authorization

    Balversa — Prior systemic therapy required

    Balversa requires prior authorization and a documented trial of at least one prior systemic therapy for locally advanced or metastatic urothelial carcinoma prior to coverage.

    • Prerequisite therapy: trial of at least one prior systemic therapy
    Prior Authorization

    Banzel — Divalproex trial required

    Banzel (rufinamide) requires prior authorization and a documented trial of divalproex (or equivalent) as a prerequisite Part D drug before approval.

    • Prerequisite therapy: trial of divalproex or equivalent
    Prior Authorization

    PA required — prerequisite therapy may be mandated

    Prior authorization is required for many listed products; coverage for some drugs additionally requires documented trials of specified alternative therapies or Part D drugs as noted in each product entry.

    Prior Authorization

    Benlysta — PA and 1‑year duration

    Benlysta requires prior authorization for medically‑accepted indications and is authorized with a coverage duration of 1 year.

    • Coverage duration: 1 year
    Prior Authorization

    PA with documented prerequisite therapies (oncology examples)

    Some products require prior authorization with documentation of prerequisite Part D drug use or disease‑specific prerequisite trials (examples include combination with nivolumab for first‑line advanced RCC, prior sorafenib for HCC, or VEGFR‑targeted therapy for DTC).

    • First‑line advanced RCC: must be used in combination with nivolumab
    • HCC: prior trial of sorafenib required
    • Radioiodine‑refractory DTC: trial of VEGFR‑targeted therapy required
    Prior Authorization

    Glatopa — PA; no prerequisite Part D drug

    Glatiramer acetate (Glatopa) requires prior authorization with a coverage duration of 1 year; a prerequisite Part D drug is not required.

    • Coverage duration: 1 year
    • No prerequisite Part D drug required
    Prior Authorization

    Copiktra — PA and prior‑lines requirement

    Copiktra requires prior authorization for relapsed or refractory CLL and documentation of at least two prior therapies as a prerequisite.

    • Prerequisite: at least two prior therapies
    Prior Authorization

    Cosentyx — PA with indication‑specific trial requirements

    Cosentyx requires prior authorization; coverage varies by indication and may require diagnostic evidence and trial of an NSAID for ankylosing spondylitis and related indications.

    • Cannot be used in combination with another biologic/targeted DMARD
    • AS/non‑radiographic axSpA/ERA: trial of one NSAID required
    • Reauthorization requires documentation of positive clinical response
    Prior Authorization

    Cotellic — PA; BRAF‑mutant melanoma requirements

    Cotellic requires prior authorization for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation; prerequisite therapy reference includes vemurafenib.

    • Prerequisite therapy: vemurafenib (as noted)
    Prior Authorization

    Cresemba & Cystaran — PA and 1‑year duration (no prerequisite)

    Cresemba and Cystaran each require prior authorization with a coverage duration of 1 year; neither requires a prerequisite Part D drug.

    • Coverage duration: 1 year
    • No prerequisite Part D drug required
    Prior Authorization

    Dalfampridine — PA, baseline T25FW required; exclusion for wheelchair use

    Dalfampridine requires prior authorization for multiple sclerosis and mandates documentation of a baseline Timed 25‑Foot Walk (T25FW) test prior to initiation; use is excluded if the patient is wheelchair bound or becomes wheelchair bound.

    • Baseline T25FW documentation required prior to initiation
    • Excluded if patient is wheelchair‑bound or becomes wheelchair‑bound
    Documentation Required

    Dalfampridine — Baseline T25FW required

    Dalfampridine PA requires documentation of a baseline Timed 25‑Foot Walk (T25FW) test for MS prior to initiation.

    • Baseline T25FW test must be documented
    Prior Authorization

    Drizalma — PA and 1‑year coverage

    Drizalma Sprinkle requires prior authorization and is authorized with a coverage duration of 1 year.

    • Coverage duration: 1 year
    Prior Authorization

    Prior authorization required — general note

    Prior authorization is required for many specialty and Part D products; typical coverage duration is commonly set to 1 year and product‑specific prerequisite trials apply as listed.

    • Coverage duration commonly 1 year
    • Product‑specific prerequisite trials and documentation required per entry
    Prior Authorization

    Erivedge — Prescriber restriction and PA

    Erivedge requires prior authorization, is authorized for 1 year for medically‑accepted indications, and the prescribing physician must be an oncologist or dermatologist.

    • Prescriber restriction: oncologist or dermatologist
    • Coverage duration: 1 year
    Prior Authorization

    Erleada — PA and 1‑year duration

    Erleada requires prior authorization and is authorized for 1 year for medically‑accepted indications.

    • Coverage duration: 1 year
    Prior Authorization

    ESA (Procrit) — PA and duration

    Erythropoiesis stimulating agents (e.g., Procrit) require prior authorization and are authorized for 1 year subject to applicable duration/criteria.

    • Coverage duration: 1 year
    Prior Authorization

    Esbriet — PA and 1‑year coverage

    Esbriet (pirfenidone products) require prior authorization and are authorized for 1 year for medically‑accepted indications.

    • Coverage duration: 1 year
    Step Therapy

    Eucrisa — Topical steroid trial required

    Eucrisa coverage for atopic dermatitis requires prior authorization and a documented trial of one generic topical steroid (prerequisite Part D drug) prior to approval; coverage duration is 1 year.

    • Prerequisite therapy: trial of one generic topical steroid
    • Coverage duration: 1 year
    Prior Authorization

    Eulexin — Bicalutamide trial required

    Eulexin requires prior authorization and coverage requires a trial of generic bicalutamide prior to approval; authorized for 1 year.

    • Prerequisite therapy: trial of generic bicalutamide
    • Coverage duration: 1 year
    Step Therapy

    Fanapt — Two‑agent step therapy required

    Fanapt coverage for schizophrenia requires prior authorization and documented trials of two generic formulary atypical antipsychotics (examples: quetiapine, risperidone, ziprasidone) prior to approval.

    • Prerequisite therapies: two generic atypical antipsychotics (e.g., quetiapine, risperidone, ziprasidone)
    Prior Authorization

    Fasenra — Detailed PA and documentation requirements

    Fasenra prior authorization includes indication‑specific criteria (eosinophil thresholds, prior controller therapy failures, EGPA/HES evidence) and reauthorization requires documented positive clinical response; coverage duration is 1 year.

    • Eosinophilic asthma: eosinophils ≥150 cells/µL at initiation and failure of systemic or high‑dose inhaled corticosteroids plus one additional controller
    • EGPA: diagnosis and supporting evidence (e.g., histopathology) required
    • HES: eosinophils ≥1000 cells/µL at initiation
    • Cannot be used in combination with another biologic/targeted DMARD
    • Reauthorization: documentation of positive clinical response
    • Coverage duration: 1 year
    Step Therapy

    Fetzima — Prerequisite SNRI trials required

    Fetzima requires prior authorization for major depressive disorder and coverage requires documented trials of desvenlafaxine and duloxetine (prerequisite Part D drugs) prior to approval.

    • Prerequisite therapies: desvenlafaxine and duloxetine
    Prior Authorization

    PA requires prerequisite Part D drug trials (antidepressant examples)

    Prior authorization for MDD may require documented trials of specified Part D drugs; for Fetzima specifically, trials of desvenlafaxine and duloxetine are required.

    Prior Authorization

    Gilotrif — PA and EGFR mutation documentation

    Gilotrif requires prior authorization and coverage is provided as first‑line treatment for metastatic NSCLC with non‑resistant EGFR mutations detected by an FDA‑approved test.

    • Document EGFR mutation status by FDA‑approved test
    Prior Authorization

    GLP‑1 agonists — PA, documentation, and exclusion for weight‑loss only

    GLP‑1 agonists (e.g., Mounjaro, Ozempic, Rybelsus, Trulicity) require prior authorization; coverage is limited to medically‑accepted indications (T2DM) with required supporting medical records or lab evidence, and they are excluded if used solely for weight‑loss.

    • Submit medical records confirming T2DM or lab evidence (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour PG ≥200 mg/dL)
    • Excluded if used for weight‑loss only
    • Coverage duration: 1 year
    Prior Authorization

    Various products — PA and typical 1‑year duration

    Other listed specialty products require prior authorization and are typically authorized for 1 year; prerequisite therapy requirements vary by product and must be followed per each product's PA criteria.

    Prior Authorization

    Humira — PA, DMARD trial and combination exclusion

    Humira products require prior authorization for medically‑accepted indications and typically require condition‑specific prerequisite therapy trials (e.g., trial of one DMARD for RA) and cannot be used in combination with another biologic/targeted DMARD for the same condition.

    • RA: trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) required
    • Cannot be used in combination with another biologic/targeted DMARD
    • Coverage duration commonly 1 year
    Prior Authorization

    Prior authorization required — product list summary

    Prior authorization is required for the listed specialty/Part D products; coverage durations are commonly 1 year and prerequisite therapy requirements differ by product and indication.

    Prior Authorization

    Imkeldi — PA; tablet intolerance/swallowing restriction

    Imkeldi requires prior authorization and coverage for all indications requires that the patient is unable to swallow the tablet formulation or unable to achieve the prescribed dose with tablets.

    • Coverage prerequisite: inability to swallow tablet formulation OR inability to achieve prescribed dose with tablets
    Prior Authorization

    IVIG — PA (no prerequisite Part D drug required)

    Immune globulin (IVIG) products are subject to prior authorization and do not require use of a prerequisite Part D drug per the entry.

    Prior Authorization

    Inlyta — PA with combination and prerequisite requirements

    Inlyta prior authorization requires a prerequisite Part D drug for some indications and mandates combination therapy (e.g., with avelumab or pembrolizumab) for first‑line advanced renal cell carcinoma.

    • First‑line advanced RCC: combination with avelumab or pembrolizumab required
    • Prerequisite Part D drug required for some indications
    Prior Authorization

    Ivermectin 3 mg — PA and FDA‑approved indication limit

    Ivermectin tablets (3 mg) require prior authorization; coverage duration is noted as 1 year and indications are limited to FDA‑approved uses.

    • Coverage duration: 1 year
    • Indications: FDA‑approved uses
    Prior Authorization

    Deferasirox (Jadenu) — PA and 1‑year coverage

    Deferasirox (Jadenu) tablets require prior authorization and are authorized for 1 year for medically‑accepted indications.

    • Coverage duration: 1 year
    Prior Authorization

    Kalydeco — PA and 1‑year duration

    Ivacaftor (Kalydeco) requires prior authorization for FDA‑approved indications and is authorized for 1 year.

    • Coverage duration: 1 year
    Prior Authorization

    Prior authorization and coverage duration — general

    Prior authorization criteria apply across listed products and coverage duration is commonly set to 1 year unless otherwise stated.

    • Typical coverage duration: 1 year
    Prior Authorization

    Prerequisite therapy — Kevzara/Kineret examples

    Several products (e.g., Kevzara, Kineret) require prior trials of specified therapies (prerequisite Part D drugs) before coverage; document required prior therapies per product PA criteria.

    • Kevzara: trial of two specified agents (e.g., Enbrel, adalimumab variants, Rinvoq, Xeljanz/XR, Orencia) for RA
    • Kineret: trial of two specified agents for RA
    Prior Authorization

    Kerendia — SGLT2 trial required for HFpEF indication

    Kerendia coverage for CKD associated with T2DM is permitted; for treatment of heart failure with LVEF ≥40% a trial of an SGLT2 inhibitor (e.g., empagliflozin or dapagliflozin) is required unless contraindicated or intolerant.

    • Prerequisite trial: SGLT2 inhibitor for HFpEF (LVEF ≥40%) unless contraindicated/intolerant
    Prior Authorization

    Prior authorization required — examples and variations

    Prior authorization is required for each listed product; coverage durations and prerequisite therapy requirements vary by product (examples include Koselugo authorized for 1 year and Krazati requiring prior systemic therapy).

    • Koselugo: coverage duration 1 year
    • Krazati: requires prior systemic therapy (KRAS G12C NSCLC)
    • Lenvima: combination and prior anti‑angiogenic therapy requirements for certain indications
    Step Therapy

    Step therapy (ST) — formulary (ST) flag implies required prior trials

    Formulary drugs identified with (ST) require prior treatment with specified formulary drugs before coverage; check the individual product entry for the exact step‑therapy drugs required.

    Step Therapy

    Auvelity — Step therapy: prior generic antidepressant

    Auvelity requires step therapy: a trial of another generic formulary antidepressant must be documented prior to approval.

    • Document trial of another generic formulary antidepressant
    Step Therapy

    Step/combination therapy examples — oncology and hematology

    Some products require prior or combination therapy (e.g., Braftovi requires combination with binimetinib; Brukinsa requires prior trial of Calquence for MCL; Cabometyx first‑line RCC requires combination with nivolumab).

    • Braftovi: combination with binimetinib required for specified indications
    • Brukinsa: trial of Calquence required for MCL
    • Cabometyx: first‑line RCC requires combination with nivolumab
    Step Therapy

    Oncology prior‑trial requirements (sorafenib/VEGFR examples)

    Certain indications require prior trials of specified therapies before coverage (examples include prior sorafenib for HCC and prior VEGFR‑targeted therapy for DTC); absence of required prior therapy may result in denial.

    • HCC: prior trial of sorafenib required
    • Radioiodine‑refractory DTC: trial of VEGFR‑targeted therapy required
    Step Therapy

    Step therapy/trial requirements — various products

    Multiple products require documented trials of specified prior therapies or formulary alternatives (e.g., Diacomit requires trial of two generic anticonvulsants and combination use with clobazam).

    • Diacomit: trial of 2 generic anticonvulsants and combination with clobazam
    • Dihydroergotamine: two triptan trials required (one oral, one non‑oral)
    Step Therapy

    Prerequisite therapy/step requirements — documentation necessary

    Many products require trials of specified prior therapies (e.g., DMARDs for Enbrel; two generic alternatives for Epidiolex); document these prerequisite trials when submitting a PA request.

    Step Therapy

    Eucrisa — Step therapy: topical steroid trial

    Eucrisa step therapy requires a documented trial of one generic topical steroid prior to authorization for atopic dermatitis.

    • Trial of one generic topical steroid required
    Step Therapy

    Fanapt — Two‑agent step therapy

    Fanapt requires step therapy: trials of two generic formulary atypical antipsychotics must be documented prior to coverage for schizophrenia.

    • Trials of two generic atypical antipsychotics (e.g., quetiapine, risperidone, ziprasidone)
    Step Therapy

    Fasenra — Step therapy: controller failure required

    Fasenra step therapy for eosinophilic asthma requires failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier OR LABA OR LAMA).

    • Failure after systemic or high‑dose inhaled corticosteroids
    • Trial of one additional controller: leukotriene modifier OR LABA OR LAMA
    Step Therapy

    Fetzima — Prerequisite Part D drug trials required

    Fetzima requires prior trials of desvenlafaxine and duloxetine for major depressive disorder; these prerequisite Part D drugs must be trialed and documented before approval.

    • Prerequisite Part D drugs: desvenlafaxine and duloxetine
    Step Therapy

    Fetzima — Prerequisite trials (duplicate)

    Duplicate: Fetzima prerequisite therapy requires documented trials of desvenlafaxine and duloxetine prior to approval.

    Step Therapy

    Humira — Step therapy: DMARD/NSAID trial required

    Humira step therapy for rheumatoid arthritis requires a trial of at least one disease‑modifying antirheumatic drug (DMARD) prior to approval; ankylosing spondylitis requires trial of an NSAID.

    • RA: trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine)
    • AS: trial of one NSAID required
    Step Therapy

    Prerequisite/step therapy requirements — disease‑specific examples

    For certain indications, coverage requires prior trials of specified drugs (e.g., DMARDs for RA, methotrexate/leflunomide/sulfasalazine; NSAID for AS); ensure documentation of these trials in PA submissions.

    Step Therapy

    Isotretinoin — Prerequisite antibiotic or benzoyl peroxide required

    Isotretinoin coverage requires prior authorization and documented trial of either an oral antibiotic or a benzoyl peroxide topical prior to approval.

    • Prerequisite trial: oral antibiotic OR benzoyl peroxide topical
    Step Therapy

    MCL (Jaypirca) — Two‑line systemic therapy trial required

    Jaypirca coverage for mantle cell lymphoma requires prior authorization and documentation of a trial of two lines of systemic therapy including a BTK inhibitor; lack of documented prior therapies may result in denial.

    • Trial of two lines of systemic therapy (including a BTK inhibitor) required
    Prior Authorization

    Jylamvo — Methotrexate trial required

    Jylamvo requires prior authorization and a documented trial of methotrexate tablets prior to approval.

    • Prerequisite therapy: trial of methotrexate tablets
    Prior Authorization

    Kisqali — Combination endocrine therapy required

    Kisqali coverage requires combination use with an aromatase inhibitor or fulvestrant as initial endocrine‑based therapy for HR+/HER2‑ advanced/metastatic breast cancer (or following progression on endocrine therapy); prior authorization applies.

    • Combination with an aromatase inhibitor or fulvestrant required per indication
    Step Therapy

    Combination/step therapy examples — Lenvima and others

    Some products stipulate required combination or prior agents (e.g., Lenvima often requires combination with pembrolizumab or everolimus in specified RCC/EC settings); follow the product‑specific PA language for required partners.

    • Lenvima: combination with pembrolizumab or everolimus for certain indications; may require prior anti‑angiogenic therapy
    Note

    Pharmacy help desk — PA/ST request process

    For administrative assistance, the prescribing physician should contact the pharmacy help desk to request prior authorization or step therapy and verify formulary coverage.

    Documentation Required

    Prolastin‑C — Required diagnostic documentation

    For Prolastin‑C, prior authorization requests must include documentation of a congenital alpha‑1 antitrypsin deficiency phenotype consistent with PIZZ, PIZ (null), or PI (null, null).

    • Document congenital AAT phenotype (PIZZ, PIZ null, or PI null/null)
    Documentation Required

    Prerequisite therapy — Documentation required on PA

    PA requests must document indications and prerequisite therapy trials where specified (e.g., trials of listed prior therapies or Part D drugs are required for many products).

    Documentation Required

    Combination/prior‑trial documentation (oncology examples)

    When coverage requires combination use with a specific agent (e.g., nivolumab for first‑line RCC) or prior trial of a specified drug (e.g., sorafenib for HCC), documentation that the combination or prior trial is planned or completed must be provided with the PA request.

    • Document planned combination with nivolumab for first‑line RCC
    • Document prior sorafenib trial for HCC
    • Document prior VEGFR‑targeted therapy for eligible DTC
    Documentation Required

    Dalfampridine — Baseline T25FW documentation required

    Document a baseline Timed 25‑Foot Walk (T25FW) test prior to initiating dalfampridine for multiple sclerosis; this baseline measurement must be included with the PA request.

    • Include baseline T25FW test result with PA
    Documentation Required

    Biologic reauthorization — document positive clinical response

    Reauthorization for several biologic agents (e.g., Cosentyx) requires documentation of a positive clinical response to therapy at renewal.

    • Provide evidence of positive clinical response for reauthorization
    Documentation Required

    Dupixent — Required PA documentation and reauthorization evidence

    Dupixent PA requests must include documentation of diagnosis, indication‑specific prior therapy trials, and positive clinical response upon reauthorization.

    • Document indication‑specific prior trials (per Dupixent criteria)
    • Provide clinical response evidence for reauthorization
    Documentation Required

    Fasenra — Required clinical documentation and reauthorization

    Fasenra PA requests require indication‑specific clinical documentation (e.g., eosinophil counts, histopathology for EGPA, history of asthma) and reauthorization requires documented positive clinical response.

    • Eosinophil counts and other disease‑specific evidence
    • EGPA: histopathology or organ‑manifestation documentation
    • Reauthorization: positive clinical response
    Documentation Required

    Fetzima — Required medical information (prerequisite trials)

    For Fetzima PA, include documentation of trials of desvenlafaxine and duloxetine (the specified prerequisite Part D drugs) when submitting the prior authorization request.

    • Document trials of desvenlafaxine and duloxetine
    Documentation Required

    GLP‑1 agonists — Required documentation for T2DM

    When requesting PA for GLP‑1 agonists for ongoing T2DM treatment, submit medical records or lab evidence confirming the T2DM diagnosis (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour PG ≥200 mg/dL) as required.

    • Provide chart notes or labs confirming T2DM (A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hour PG ≥200 mg/dL)
    Documentation Required

    Gilotrif — EGFR mutation documentation required

    For Gilotrif coverage as first‑line treatment of metastatic NSCLC, include documentation of EGFR mutation status detected by an FDA‑approved test with the PA submission.

    • Attach EGFR mutation test result from an FDA‑approved test
    Documentation Required

    Humira — Required PA documentation and reauthorization

    For Humira PA requests (e.g., rheumatoid arthritis), document the diagnosis and a trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); reauthorization requires documentation of positive clinical response.

    • Document diagnosis of moderately to severely active RA
    • Document trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine)
    • Provide evidence of clinical response for reauthorization
    Documentation Required

    General required clinical documentation for PA/reauthorization

    Providers must document disease‑specific prerequisite therapy trials (e.g., DMARDs for RA, NSAID trial for AS) and submit positive clinical response evidence at reauthorization where specified.

    Documentation Required

    Prior therapy documentation — polycythemia vera example

    Some product entries require documentation of prior systemic therapy trials (one or two lines) for coverage of certain conditions such as polycythemia vera; include prior therapy records in the PA request.

    • Polycythemia vera: document inadequate response or intolerance to hydroxyurea
    Documentation Required

    Prerequisite therapy documentation — MCL and Jylamvo

    Where a specific prerequisite therapy is required (e.g., BTK inhibitor for MCL or methotrexate for Jylamvo), include documentation of those prior trials to avoid denial.

    • MCL (Jaypirca): document two prior systemic therapy lines including BTK inhibitor
    • Jylamvo: document methotrexate tablet trial
    Denial Risk

    Consequence of missing PA/ST requirements — denial risk

    Coverage requires meeting the clinical and/or administrative PA and ST criteria; failure to meet required PA or step‑therapy conditions may result in denial of the request.

    Denial Risk

    Prolastin‑C — Denial risk if FEV1 or diagnosis criteria unmet

    For Prolastin‑C, requests may be denied if the patient does not have the required diagnosis and an FEV1 less than 80% predicted; ensure FEV1 and diagnostic phenotype documentation are provided.

    • FEV1 must be < 80% predicted
    • Diagnosis and congenital AAT phenotype must be documented
    Denial Risk

    Budesonide ER — Explicit exclusion for UC maintenance

    Budesonide ER will not be covered for maintenance of remission in ulcerative colitis; do not submit PA requests for that use.

    Denial Risk

    RCC coverage — Combination therapy required (denial risk if absent)

    First‑line advanced renal cell carcinoma coverage for several agents (e.g., Cabometyx, Inlyta, Lenvima) requires combination use with specified immune checkpoint inhibitors (e.g., nivolumab, avelumab, pembrolizumab); requests lacking the required combination may be denied.

    • Cabometyx: first‑line RCC requires combination with nivolumab
    • Inlyta: first‑line RCC requires combination with avelumab or pembrolizumab
    • Lenvima: certain RCC indications require combination with pembrolizumab
    Denial Risk

    HCC — Sorafenib prior trial required (denial risk)

    Hepatocellular carcinoma coverage for some agents requires a prior trial of sorafenib; absence of documentation of such a trial may lead to denial.

    • Document prior sorafenib trial for HCC
    Denial Risk

    DTC — VEGFR‑targeted therapy trial required (denial risk)

    Locally advanced or metastatic differentiated thyroid cancer that is radioactive iodine‑refractory or ineligible requires documentation of a trial of a VEGFR‑targeted therapy for coverage; failure to document this prior trial may result in denial.

    • Document prior VEGFR‑targeted therapy trial for eligible DTC
    Denial Risk

    Dalfampridine — Exclusion if wheelchair‑bound

    Dalfampridine is excluded for use if the patient is wheelchair bound or becomes wheelchair bound; do not approve PA requests for wheelchair‑bound patients.

    Denial Risk

    Dalfampridine — Denial risk if baseline T25FW not provided

    Documentation of a baseline Timed 25‑Foot Walk (T25FW) test is required prior to initiating dalfampridine for MS; absence of this baseline may result in denial.

    • Baseline T25FW must be provided with PA
    Denial Risk

    Diacomit — Denial risk if prior trials or clobazam combination not documented

    Diacomit coverage requires documented trials of two generic anticonvulsants and combination use with clobazam; lack of these documented trials may lead to denial.

    • Trial of 2 generic anticonvulsants required
    • Combination use with clobazam required
    Denial Risk

    Dihydroergotamine — Triptan trial requirement (denial risk)

    Dihydroergotamine nasal spray requires documented trials of two triptans on the formulary (one oral and one non‑oral) prior to coverage; missing these trials may result in denial.

    • Trial of one oral triptan and one non‑oral triptan required
    Denial Risk

    Dupixent — Clinical/reauthorization requirements (denial risk)

    Dupixent coverage requires adherence to diagnosis‑specific criteria (including age/weight and prior therapy/trial requirements) and reauthorization requires documentation of positive clinical response; failure to meet these may result in denial.

    Denial Risk

    Combination biologic exclusion — Denial risk

    Use of any product in combination with another biologic or targeted DMARD indicated for the same condition is not allowed and may trigger denial where explicitly stated in product summaries.

    • Combination with another biologic/targeted DMARD for same condition is prohibited where noted
    Denial Risk

    Fasenra — Concurrent biologic exclusion (denial risk)

    Fasenra cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; requests that include concurrent biologics may be denied.

    Denial Risk

    Prerequisite Part D trials — Denial risk if undocumented

    Failure to document required prerequisite Part D drug trials (e.g., desvenlafaxine and duloxetine for Fetzima) may trigger denial of the PA request.

    Denial Risk

    GLP‑1 agonists — Weight‑loss‑only exclusion (denial risk)

    Requests to use GLP‑1 agonists solely for weight‑loss purposes are excluded and may be denied; ensure indication documentation supports T2DM when submitting PA.

    • GLP‑1 agonists excluded if used for weight‑loss only
    Denial Risk

    Humira — Combination therapy exclusion (denial risk)

    Humira requests proposing combination use with another biologic or targeted DMARD for the same condition are not permitted and may be denied.

    Denial Risk

    Combination therapy exclusion — General

    General exclusion language: products noted in the document cannot be used in combination with another biologic or targeted DMARD for the same condition where the product entry states this exclusion; non‑compliance may cause denial.

    Documentation Required

    Reauthorization — Positive clinical response required

    Reauthorization of most specialty biologic therapies requires documentation of positive clinical response to therapy; lack of response documentation may prevent renewal.

    Documentation Required

    Imkeldi — Swallowing/tablet dosing documentation required (denial risk)

    Imkeldi coverage requires documentation that the patient is unable to swallow tablet formulation or cannot achieve the prescribed dose with tablets; absence of this documentation may result in denial.

    • Document inability to swallow tablets or inability to achieve prescribed tablet dose
    Denial Risk

    Inlyta — Combination requirement for first‑line RCC (denial risk)

    Coverage for first‑line advanced renal cell carcinoma with Inlyta requires combination use with avelumab or pembrolizumab; missing documentation of the combination may trigger denial.

    • Document planned combination with avelumab or pembrolizumab for first‑line RCC
    Prior Authorization

    Itovebi — Prerequisite fulvestrant noted (incomplete)

    Itovebi coverage notes a requirement related to fulvestrant for endocrine‑resistant, PIK3CA‑mutated HR‑positive disease; source text is truncated—confirm full prerequisite in the product PA entry.

    Denial Risk

    Polycythemia vera — Prerequisite therapy documentation may trigger denial

    For polycythemia vera and similar indications, failure to document inadequate response or intolerance to the required prior therapy (e.g., hydroxyurea) may lead to denial of coverage.

    • Document inadequate response or intolerance to hydroxyurea for polycythemia vera
    Step Therapy

    MCL (Jaypirca) — Step requirement and denial risk

    Mantle cell lymphoma coverage (Jaypirca) requires documentation of two prior lines of systemic therapy including a BTK inhibitor; absence of this documented history may result in denial.

    • Two prior systemic therapy lines including BTK inhibitor must be documented
    Denial Risk

    Kevzara — Combination biologic exclusion (denial risk)

    Kevzara must not be used in combination with another biologic or targeted DMARD for the same condition; such combination requests are not permitted and may be denied.

    Denial Risk

    Prerequisite systemic therapy — Denial risk if unmet

    Requests may be denied if prerequisite systemic therapy or prior Part D drug requirements are not met (e.g., Krazati requires prior systemic therapy; some Lenvima indications require prior anti‑angiogenic therapy or specific combinations).

    • Krazati: prior systemic therapy for KRAS G12C‑mutated NSCLC required
    • Lenvima: prior anti‑angiogenic therapy or combination partner documentation may be required
    Note

    Background — PA/ST program purpose

    Background: This formulary document lists drugs subject to prior authorization and/or step therapy to ensure appropriate and cost‑effective therapy; clinical criteria are based on the Blues' Pharmacy & Therapeutics Committee recommendations.

    Note
    Note
    Note
    Note
    Note
    >=1000 cells/µL at initiation
    EGPA documentationDiagnosis of eosinophilic granulomatosis with polyangiitis and history or presence of asthma required
    Definition
    A requirement that members try and fail specified formulary drugs prior to coverage of a non-formulary or later-line drug.
    ScopeDrugs identified with (ST) on the formulary require prior treatment with specified formulary drugs before coverage.
    Provider actionContact pharmacy help desk to initiate step-therapy exceptions or document prior trials as required.
    inv-178: Prerequisite Part D drug definition
    DefinitionA previously used Part D medication whose trial or failure may be required before coverage of the listed product (document notes whether required per product).
    Role in PAPA summaries note when a prerequisite Part D drug is required or not for product approval.
    ExamplesEbglyss and Copiktra entries indicate prerequisite Part D drug requirements in their PA notes.
    inv-179: Timed 25-Foot Walk (T25FW) definition
    DefinitionA baseline functional mobility test (Timed 25-Foot Walk, T25FW) required prior to initiating dalfampridine for multiple sclerosis.
    UseDocuments baseline walking speed to assess treatment benefit and support PA requests.
    DocumentationPA requires submission of baseline T25FW test prior to initiation for MS indication.
    inv-180: T25FW duplicate definition
    DefinitionRequirement to provide the baseline Timed 25-Foot Walk (T25FW) measurement — duplicate reference reinforcing that T25FW documentation is required prior to dalfampridine initiation.
    ContextUsed to verify eligibility and monitor response to dalfampridine in persons with MS.
    Exclusion noteDalfampridine is excluded if the patient is wheelchair bound or becomes wheelchair bound; T25FW may be unobtainable in that scenario.
    inv-181: Medically-accepted Indications
    DefinitionIndications recognized as medically accepted for the given product (phrase used repeatedly in product entries).
    ApplicationPA coverage is provided for medically-accepted or FDA-approved indications when product-specific criteria are met.
    ReauthorizationReauthorization generally requires documentation of positive clinical response for medically-accepted indications.
    inv-182: Prerequisite Part D drug (definition duplicate)
    DefinitionA previously used Part D medication whose trial or failure may be required before coverage of the listed product (document notes whether required per product).
    DocumentationPA requests must document prior Part D drug trials when specified in a product's PA criteria.
    ExamplesSome products (e.g., Copiktra) explicitly require prior Part D therapies; others (e.g., Glatopa) do not.
    inv-183: Non-resistant EGFR mutation definition
    DefinitionEGFR mutations in NSCLC that are sensitive to EGFR-targeted therapy as determined by an FDA-approved test (non-resistant EGFR mutation).
    DocumentationGilotrif coverage requires documentation of EGFR mutation status detected by an FDA-approved test.
    Coverage roleGilotrif is covered as first-line treatment for metastatic NSCLC with non-resistant EGFR mutations.
    inv-184: Imkeldi restriction definition
    RestrictionCoverage for Imkeldi requires that the patient is unable to swallow the tablet formulation or is unable to achieve the prescribed dose with the tablet formulation.
    ScopeApplies to all Imkeldi indications in the PA summary.
    Prerequisite noteSome Imkeldi criteria also require use of a prerequisite Part D drug as specified in product entries.
    inv-185: Isotretinoin prerequisite therapy definition
    Prerequisite therapyCoverage for isotretinoin requires trial of either an oral antibiotic OR a benzoyl peroxide-containing topical prior to approval.
    ApplicationThis trial requirement is documented in product PA entries for isotretinoin formulations.
    PurposeTo ensure prior, less-risky therapies have been attempted before initiating isotretinoin.
    inv-186: Prerequisite Part D drug (definition duplicate)
    DefinitionA previously used Part D medication whose trial or failure may be required before coverage of the listed product (document notes whether required per product).
    Provider actionDocument trials of specified Part D drugs in the PA request when indicated (e.g., Fetzima requires desvenlafaxine and duloxetine).
    Policy varianceSome product entries explicitly state that a prerequisite Part D drug is not required (e.g., Glatopa, Koselugo).